news
-
11 January 2021Immunocore announces closing of $75.0 Million Series C round
Immunocore, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the completion of a $75.0 million Series C private financing round.
Led by an existing investor, the Series C financing included support from existing investors and funds and accounts managed by BlackRock. The proceeds will enable Immunocore to further expand and accelerate its growing clinical stage pipeline of ImmTAX™ (Immune mobilising monoclonal TCRs Against Cancer, Infectious Diseases and Autoimmune) molecules, including its lead program tebentafusp (IMCgp100).
Immunocore also announces that it has closed a $100.0 million senior secured loan facility with Oxford Finance LLC and intends to use the loan proceeds for general corporate purposes and to have available as needed to fund a potential commercial launch of tebentafusp.
Bahija Jallal, Chief Executive Officer of Immunocore, said: “This successful financing represents another validating milestone for Immunocore as we continue our pioneering work in the field of soluble, bispecific TCR immunotherapies to treat a broad range of diseases. The support of our new and existing investors represents a further endorsement of the potential of our powerful technology platform. Following the recent positive Phase 3 data for tebentafusp, we are working to progress this investigational agent through the regulatory process as a potential new treatment to metastatic uveal melanoma patients with a high unmet need.”
Interim results from the IMCgp100-202 Phase 3 clinical trial are expected to be presented at an upcoming scientific conference and to be submitted for publication in a peer-reviewed journal. If approved, Immunocore believes tebentafusp would be the first new therapy for the treatment of metastatic uveal melanoma in 40 years.
Related
Immunocore announces dosing of first patient with fourth ImmTAC
First Site in Global Uveal Melanoma Patient Registry Now Open
Immunocore announces dosing of first patient with third ImmTAC® bispecific
Detailed Review of Tebentafusp (IMCgp100) in Metastatic Uveal Melanoma Published in Issue of Cancers
Immunocore’s Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma
Immunocore appoints Bahija Jallal as Chief Executive Officer
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
Immunocore strengthens IP position in the field of TCR-based therapeutics
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
Immunocore Announces Management Change
Immunocore wins Large Business of the Year at the 2018 Vale4Business Awards
Immunocore Announces Leadership Change
Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer
Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK
Immunocore Announces Third Oncology Target Selected in Discovery Collaboration with GlaxoSmithKline
Immunocore identifies second novel ImmTAC® in the GSK collaboration
Immunocore wins Financing Deal of the Year at the 12th Annual SCRIP Awards 2016
Immunocore Appoints Paul Fry as Chief Financial Officer
Immunocore Ranked in the Sunday Times Hiscox Tech Track 100
Immunocore Wins Private UK Life Science Company of the Year at Biotech and Money Assembly and Awards
Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma
Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma
Immunocore Starts Clinical Trial with IMCgp100 in Combination with MedImmune Immunotherapies Durvalumab and Tremelimumab
Immunocore and GlaxoSmithKline Select First ImmTAC Clinical Candidate in Discovery Collaboration
Immunocore expands its senior management team and opens US Office
Immunocore wins Biotech of the Year at the SCRIP Awards 2015